• About Us
    • Contact Us
    • Login
    • ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
About Us Contact Us Login ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
Grand Rounds

FEMME RCT Results: Myomectomy or Uterine Artery Embolization for Uterine Fibroids?

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • Manyonda et al. (NEJM, 2020) examined outcomes following myomectomy, vs uterine-artery embolization

METHODS:

  • Multicenter, randomized, open-label trial
    • A Randomized Trial of Treating Fibroids with Either Embolisation or Myomectomy to Measure the Effect on Quality of Life Among Women Wishing to Avoid Hysterectomy (FEMME Trial)
    • 29 centers in the UK
  • Participants
    • Symptomatic uterine fibroids
    • Did not opt for hysterectomy
  • Interventions
    • Myomectomy
      • Open abdominal, laparoscopic, or hysteroscopic
    • Uterine artery embolization
  • Study design
    • Randomization balanced for the following
      • Longest dimension of the largest fibroid (≤7 cm vs. >7 cm) | Number of fibroids (1 to 3 vs. 4 to 10 vs. >10) | Whether pregnancy was desired in the future (yes vs. no)
    • Quality of life (QOL) assessed with Uterine Fibroid Symptom and Quality of Life (UFS-QOL) questionnaire at 2 years
      • Scores range from 0 to 100 | Higher scores indicating a better quality of life
    • Analysis was by intention to treat
  • Primary outcome
    • Fibroid-related quality of life

RESULTS:

  • Total of 254 women
    • Myomectomy: 127 women (105 underwent the procedure)
    • Uterine-artery embolization: 127 (98 underwent the procedure)
    • Primary outcome data were available for 81% of the women (206)
  • Intention to treat analysis: Myomectomy group reported significantly higher quality of life scores at 2 years
    • Myomectomy group: 84.6±21.5
    • Embolization group: 80.0±22.0
    • Mean adjusted difference with complete case analysis
      • 8.0 points (95% CI, 1.8 to 14.1; P=0.01)
  • Similar results noted at 6 months and at a year  
  • Perioperative and postoperative complications did not differ between groups (P=0.40)
    • Myomectomy group: 29%
    • Embolization group: 24%
  • Pregnancy reported within 2 years
    • Myomectomy group: 4%
    •  Embolization group: 8%
  • Need for additional fibroid-related procedure within 2 years
    • Myomectomy group: 7%
    • Embolization group: 16%

CONCLUSION:

  • Quality of life scores at 2 years were significantly higher in women opting for myomectomy vs uterine-artery embolization
  • In addition, the authors state

The substantially higher number of surgical reinterventions in the uterine-artery embolization group than in the myomectomy group during 2 years of follow-up may be explained in part by the lower quality of life reported in the uterine-artery embolization group

Learn More – Primary Sources:

Uterine-Artery Embolization or Myomectomy for Uterine Fibroids

Now You Can Get ObG Clinical Research Summaries Direct to Your Phone

ObGFirst® – Try It Free! »

image_pdfFavoriteLoadingFavorite
< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

What Uterine-Sparing Treatment for Fibroids Has the Best Outcomes?
Intervention Comparison for the Treatment of Uterine Fibroids
High-Intensity Ultrasound for Fibroids – What are the Pregnancy Outcomes?
Uterine Artery Embolization, Focused Ultrasound, or Hysterectomy for Fibroids?

Legal Disclaimer Click To Expand

This website (the “Website”) is a service made available by The ObG Project LLC, its partners, affiliates or subsidiaries (“Provider”). This Website provides general information related to the law and is designed to help users safely cope with their own legal needs. This website does not provide legal advice and Provider is not a law firm. None of our customer service representatives are lawyers and they also do not provide legal advice. Although we go to great lengths to make sure our information is accurate and useful, we recommend you consult a lawyer if you want legal advice. No attorney-client or confidential relationship exists or will be formed between you and Provider or any of our representatives.
This website is not intended to be a source for legal advice, and thus the reader should not rely on any information provided in this website as such. Readers should not consider the information provided to be an invitation for an attorney-client relationship, and should always seek the advice of competent counsel in the reader’s home jurisdiction. Provider may provide links to third party websites. These links are provided only as a convenience. Linked websites are not reviewed, controlled or examined by Provider and Provider is not responsible for the information, advertising, products, resources or other materials, of any linked site or any link contained in a linked site. The inclusion of any link does not imply endorsement by Provider. In addition, please be aware that your use of any linked site is subject to the terms and conditions applicable to that site. Please direct any questions regarding linked sites to the webmaster of that site.

Sections

  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • COVID-19

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site